Drug Profile
Trastuzumab emtansine - Immunogen/Roche
Alternative Names: Ado-trastuzumab emtansine; DM1-trastuzumab immunoconjugate; Herceptin-DM1; Kadcyla; PRO-132365; R3502; RG 3502; RG3502-10; RO 5304020; T-DM1; Trastuzumab-DM1; Trastuzumab-DM1 immunoconjugate; Trastuzumab-MCC-DM1; Trastuzumab-MCC-DM1 antibody-drug conjugate; Trastuzumab–SMCC–DM1 conjugateLatest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Genentech; ImmunoGen
- Developer Chugai Pharmaceutical; Dana-Farber Cancer Institute; Genentech; Memorial Sloan-Kettering Cancer Center; Roche; University College London
- Class Antineoplastics; Drug conjugates; Immunotoxins; Macrolides; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer
- Phase II/III Gastric cancer
- Phase II Bladder cancer; Lung cancer; Non-small cell lung cancer; Salivary gland cancer; Solid tumours; Urogenital cancer
Most Recent Events
- 27 Feb 2024 Genentech completes a phase II trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO) (NCT04632992)
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 08 Dec 2023 Efficacy and adverse events data from the phase III KATHERINE trial in Breast cancer released by Genentech